Clinical Trial Update: Doravirine and Weight Gain in Antiretroviral Naive [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating doravirine and weight gain in antiretroviral-naive participants was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus

Drugs mentioned

• Doravirine (doravirine)

Snippet

Sponsor: Prism Health North Texas | Conditions: Body Weight Changes, Human Immunodeficiency Virus | Phase 3 | Status: WITHDRAWN